Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Vascular cognitive impairment: disease mechanisms and therapeutic implications.

Levine DA, Langa KM.

Neurotherapeutics. 2011 Jul;8(3):361-73. doi: 10.1007/s13311-011-0047-z. Review.

2.

Mixed dementia: emerging concepts and therapeutic implications.

Langa KM, Foster NL, Larson EB.

JAMA. 2004 Dec 15;292(23):2901-8. Review.

PMID:
15598922
3.

Rivastigmine for vascular cognitive impairment.

Birks J, McGuinness B, Craig D.

Cochrane Database Syst Rev. 2013 May 31;(5):CD004744. doi: 10.1002/14651858.CD004744.pub3. Review.

PMID:
23728651
4.

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia.

Stroke. 2011 Sep;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21. Review.

5.

Understanding and treating vascular cognitive impairment.

Gorelick PB, Nyenhuis D.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):425-37. doi: 10.1212/01.CON.0000429174.29601.de. Review.

PMID:
23558487
6.

Vascular cognitive impairment: current concepts and clinical developments.

Moorhouse P, Rockwood K.

Lancet Neurol. 2008 Mar;7(3):246-55. doi: 10.1016/S1474-4422(08)70040-1. Review.

PMID:
18275926
7.

A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.

Buckley JS, Salpeter SR.

Drugs Aging. 2015 Jun;32(6):453-67. doi: 10.1007/s40266-015-0266-9. Review.

PMID:
25941104
8.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314
9.

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.

Burns A, O'Brien J; BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology.

J Psychopharmacol. 2006 Nov;20(6):732-55. Review.

PMID:
17060346
10.

Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review.

Leroi I, Collins D, Marsh L.

J Neurol Sci. 2006 Oct 25;248(1-2):104-14. Epub 2006 Jun 27. Review.

PMID:
16806271
11.

Neuropsychological assessment and cerebral vascular disease: the new standards.

Godefroy O; GRECOG-VASC study group, Leclercq C, Bugnicourt JM, Roussel M, Moroni C, Quaglino V, Beaunieux H, Taillia H, Nédélec-Ciceri C, Bonnin C, Thomas-Anterion C, Varvat J, Aboulafia-Brakha T, Assal F.

Rev Neurol (Paris). 2013 Oct;169(10):779-85. doi: 10.1016/j.neurol.2013.07.009. Epub 2013 Aug 30. Review.

PMID:
23999023
12.

Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M.

Ann Intern Med. 2008 Mar 4;148(5):379-97. Review.

PMID:
18316756
13.

Vascular cognitive impairment.

Rincon F, Wright CB.

Curr Opin Neurol. 2013 Feb;26(1):29-36. doi: 10.1097/WCO.0b013e32835c4f04. Review.

PMID:
23254555
14.

Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia.

Román GC, Sachdev P, Royall DR, Bullock RA, Orgogozo JM, López-Pousa S, Arizaga R, Wallin A.

J Neurol Sci. 2004 Nov 15;226(1-2):81-7. Review.

PMID:
15537526
15.

Vascular cognitive impairment and post-stroke cognitive deficits.

Shim H.

Curr Neurol Neurosci Rep. 2014 Jan;14(1):418. doi: 10.1007/s11910-013-0418-4. Review.

PMID:
24272272
16.

Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people.

Malouf R, Grimley Evans J.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004514. doi: 10.1002/14651858.CD004514.pub2. Review.

PMID:
18843658
17.

The concept of vascular cognitive impairment.

Erkinjuntti T, Gauthier S.

Front Neurol Neurosci. 2009;24:79-85. doi: 10.1159/000197886. Epub 2009 Jan 26. Review.

PMID:
19182465
18.

Memantine for dementia.

Areosa SA, Sherriff F.

Cochrane Database Syst Rev. 2003;(3):CD003154. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD003154.

PMID:
12917950
19.

Vascular dementia. Advances in nosology, diagnosis, treatment and prevention.

Román GC.

Panminerva Med. 2004 Dec;46(4):207-15. Review.

PMID:
15876977
20.

Current concepts in vascular cognitive impairment and pharmacotherapeutic implications.

Rojas-Fernandez CH, Moorhouse P.

Ann Pharmacother. 2009 Jul;43(7):1310-23. doi: 10.1345/aph.1L703. Epub 2009 Jul 7. Review.

PMID:
19584390

Supplemental Content

Support Center